PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 28, 2025Journal of Neurochemistry0 citations

Unveiling the Therapeutic Potential of D2AAK1 and Its Derivatives: Mechanistic Insights and Applications in Neurodegenerative Disease Treatment

View Full Paper
MJMichał K. JastrzębskiPWPiotr WójcikAMAkanksha Mudgal

Key Points

  • D2AAK1 derivatives improved cell viability significantly, indicating their potential in neurodegenerative treatments.
  • The study found that one D2AAK1 derivative notably reversed memory impairment in a murine model of Alzheimer's disease.
  • Mechanistic insights showed D2AAK1 modulates cytoprotective proteins and reduces pro-apoptotic factors effectively.
  • These findings highlight D2AAK1's promise as a novel therapeutic agent against neurodegenerative diseases.

Abstract

ABSTRACT The global rise in life expectancy has been accompanied by a growing prevalence of neurodegenerative diseases, such as Alzheimer's disease (AD). These complex disorders arise from multiple pathogenic factors and biological pathways, necessitating the development of multi‐target therapeutic strategies. D2AAK1, discovered by our group, has emerged as a promising candidate due to its cytoprotective, antioxidant, and procognitive properties. This study aimed to further elucidate the mechanisms underlying the action of D2AAK1 and its derivatives, with a focus on their potential for neuroprotection and cognitive enhancement. The effect of D2AAK1 on cell viability was evaluated under normal conditions and during H 2 O 2 ‐induced oxidative stress using the resazurin assay. p38 MAPK activity was measured through cell‐based ELISA. mRNA expression was analyzed using a two‐step quantitative PCR method, and enzymatic effects were assessed via photometric, fluorescence, and luminescence techniques. Behavioral studies in murine models were performed to investigate the influence of the compounds on memory processes. It was found that D2AAK1 and its derivatives significantly enhanced cell viability, with some derivatives exhibiting greater potency than D2AAK1. In vivo, one derivative notably improved memory performance and reversed scopolamine‐induced memory impairment in the novel object recognition test in male Swiss mice. Mechanistic studies revealed that D2AAK1 increased the expression of cytoprotective proteins such as Bcl‐2 and HO‐1, while concurrently reducing the expression and activity of pro‐apoptotic factors, including caspase‐3, p38 MAPK, and MAO‐B. These dual actions culminated in enhanced cellular resilience and viability, translating into improved cognitive outcomes. The findings suggest that D2AAK1 and its derivatives, through their multi‐factor mechanism of action, hold promise as therapeutic agents for the treatment of neurodegenerative diseases. image

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Jastrzębski et al. (2025) studied this question.

synapsesocial.com/papers/68d90a0141e1c178a14f6128https://doi.org/10.1111/jnc.70232
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Exploring the Protective Effects of Two Alkaloids <b>1</b> and <b>2</b> from <i>Aspergillus terreus</i> C23–3 on Neuronal Cells by Combining Bioinformatics Prediction and Experimental Verification2025
  2. 2Alpha‐Ketoglutarate Ameliorates Synaptic Plasticity Deficits in <scp>APP</scp>/<scp>PS1</scp> Mice Model of Alzheimer's Disease2025
  3. 3The Mitochondrial Guardian α‐Amyrin Mitigates Alzheimer's Disease Pathology via Modulation of the DLK‐SARM1‐ULK1 Axis2026 · 2 citations
  4. 4Daphnetin protects neurons in an Alzheimer disease mouse model and normal rat neurons by inhibiting BACE1 activity and activating the Nrf2/HO-1 pathway2024
  5. 5KBN2202, a Salicylic Acid Derivative, Preserves Neuronal Architecture, Enhances Neurogenesis, Attenuates Amyloid and Inflammatory Pathology, and Restores Recognition Memory in 5xFAD Mice at an Advanced Stage of AD Pathophysiology2025